Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MIRACLE (Methotrexate Inadequate Response Patient With Rheumatoid Arthritis Treated by Adalimumab in Combination With Low-dose Methotrexate) Study

Trial Profile

MIRACLE (Methotrexate Inadequate Response Patient With Rheumatoid Arthritis Treated by Adalimumab in Combination With Low-dose Methotrexate) Study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Methotrexate (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms MIRACLE
  • Most Recent Events

    • 03 Jun 2023 Primary endpoint has not been met (Simple Disease Activity Index (SDAI) Remission Rate (ADA/MTX-Reduced Dose Group)) , according to Results presented at the 24th Annual Congress of the European League Against Rheumatism
    • 03 Jun 2023 Primary endpoint has not been met (Simple Disease Activity Index (SDAI) Remission Rate (ADA/MTX-Maximum Tolerated Dose Group)) , according to Results presented at the 24th Annual Congress of the European League Against Rheumatism
    • 03 Jun 2023 Results assessing association between the concentrations of MTX-PGs with efficacy and safety through week 48 presented at the 24th Annual Congress of the European League Against Rheumatism
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top